Checkpoint Therapeutics, Inc.
CKPTNASDAQHealthcare
$4.26
+$0.00(+0.00%)
Market Cap$367723200
P/E Ratio—
52W High$4.5
52W Low$1.8
Checkpoint Therapeutics, Inc. (CKPT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CKPT · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: May 13, 2025EPS Actual
-$0.19
Est. -$0.17 · -11.8%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2025
FY ends December
Report Date
May 13, 2025
After Market Close
▼ Miss EPS
CKPT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 11, 2026 | — | — | — | — | — | — |
| ◌ Q4 FY2025 | Nov 10, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 11, 2025 | -$0.02 | — | — | — | $0.01B | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.17 | -$0.19 | -11.8% | — | $0.00B | — |
| ▼ Q1 FY2025 | Mar 28, 2025 | -$0.22 | -$0.69 | -213.6% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.15 | -$0.23 | -53.3% | — | $0.00B | — |
| ▲ Q3 FY2024 | Aug 12, 2024 | -$0.29 | -$0.18 | +37.9% | $0.00B | $0.00B | +105.0% |
| ▲ Q2 FY2024 | May 10, 2024 | -$0.37 | -$0.33 | +10.8% | — | $0.00B | — |
Q2 FY2026
May 11, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 10, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 11, 2025
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.17
EPS Surpr.
-11.8%
Revenue
—
Q1 FY2025
Mar 28, 2025Miss
EPS Actual
-$0.69
EPS Est.
-$0.22
EPS Surpr.
-213.6%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.23
EPS Est.
-$0.15
EPS Surpr.
-53.3%
Revenue
—
Q3 FY2024
Aug 12, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$0.29
EPS Surpr.
+37.9%
Revenue
$0.00B
Q2 FY2024
May 10, 2024Beat
EPS Actual
-$0.33
EPS Est.
-$0.37
EPS Surpr.
+10.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.58 | $0.58 | $0.58 | 1 |
| Q3 FY2028 | $0.57 | $0.57 | $0.57 | 1 |
| Q2 FY2028 | $0.57 | $0.57 | $0.57 | 1 |
| Q1 FY2028 | $0.55 | $0.55 | $0.55 | 1 |
| Q4 FY2027 | $1.59 | $1.59 | $1.59 | 1 |
| Q3 FY2027 | $1.55 | $1.55 | $1.55 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2025 | May 13, 2025 | -11.8% | $4.16 | $4.15 | -0.24% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -213.6% | $4.03 | $4.04 | +0.25% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -53.3% | $3.19 | $3.45 | +8.15% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +37.9% | $2.25 | $2.31 | +2.67% |
| ▲ Q2 FY2024 | May 10, 2024 | +10.8% | $1.56 | $1.50 | -3.85% |
| ▼ Q1 FY2024 | Mar 22, 2024 | -48.6% | $1.90 | $1.94 | +2.11% |
| ▲ Q4 FY2023 | Nov 13, 2023 | +65.9% | $1.78 | $1.81 | +1.69% |
| ▼ Q3 FY2023 | Aug 14, 2023 | -26.5% | $2.14 | $2.09 | -2.34% |
Q2 FY2025-0.24%
Report Date
May 13, 2025
EPS Beat/Miss
-11.8%
Price Before
$4.16
Price After
$4.15
Q1 FY2025+0.25%
Report Date
Mar 28, 2025
EPS Beat/Miss
-213.6%
Price Before
$4.03
Price After
$4.04
Q4 FY2024+8.15%
Report Date
Nov 12, 2024
EPS Beat/Miss
-53.3%
Price Before
$3.19
Price After
$3.45
Q3 FY2024+2.67%
Report Date
Aug 12, 2024
EPS Beat/Miss
+37.9%
Price Before
$2.25
Price After
$2.31
Q2 FY2024-3.85%
Report Date
May 10, 2024
EPS Beat/Miss
+10.8%
Price Before
$1.56
Price After
$1.50
Q1 FY2024+2.11%
Report Date
Mar 22, 2024
EPS Beat/Miss
-48.6%
Price Before
$1.90
Price After
$1.94
Q4 FY2023+1.69%
Report Date
Nov 13, 2023
EPS Beat/Miss
+65.9%
Price Before
$1.78
Price After
$1.81
Q3 FY2023-2.34%
Report Date
Aug 14, 2023
EPS Beat/Miss
-26.5%
Price Before
$2.14
Price After
$2.09
Avg Beat Reaction+0.17%
Avg Miss Reaction+1.59%
Beat Rate3 / 8 quarters
Largest Move+8.15% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CKPT ends December
Checkpoint Therapeutics, Inc. (CKPT) most recently reported earnings on May 13, 2025 for Q2 FY2025, posting EPS of $-0.19 — missing the analyst consensus of $-0.17 by -11.8%. The next CKPT earnings date is expected around September 1, 2026.
Each quarter, investors track CKPT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CKPT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CKPT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CKPT earnings · 5 questionsCheckpoint Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CKPT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CKPT historically reports after market close (AMC).
CKPT earnings datewhen is CKPT earningsCKPT next earnings datewhen does CKPT report earningsCKPT earnings calendar
▸ Source: FMP · Checkpoint Therapeutics, Inc. SEC filings · US GAAP · Checkpoint Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026